Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
作者： Giuseppe Bronte , Sergio Rizzo , Laura La Paglia , Vincenzo Adamo , Sergio Siragusa
DOI: 10.1016/S0305-7372(10)70016-5
关键词: Adenocarcinoma 、 Epidermal growth factor receptor 、 Tyrosine kinase 、 Adenocarcinoma of the lung 、 Gene mutation 、 KRAS 、 Immunology 、 Carcinogenesis 、 Mutation 、 Medicine 、 Cancer research
摘要: The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate with both carcinogenesis and response to targeted drugs. Several alterations have been defined as "driver mutations". These are responsible for initiation maintenance malignancy. epidermal growth factor receptor (EGFR) pathway is main regulator cell function cancer development. It a widely role in occurrence driver mutations. Up till now EGFR gene mutations, KRAS mutations EML4-ALK fusion genes most recognized involved biology clinical management adenocarcinoma. In this review we report bases that led application detection such genetic impairments. Subsequently discuss studies regarding prognostic predictive value anti-EGFR tyrosine kinase inhibitors (TKI) same We also provide potential algorithm guide choice best treatment patients
elsevier.com
sci-hub.se 参考文章(88)
William Pao, Marc Ladanyi, Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clinical Cancer Research. ,vol. 13, pp. 4954- 4955 ,(2007) , 10.1158/1078-0432.CCR-07-1387
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer, Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis Journal of Cellular and Molecular Medicine. ,vol. 14, pp. 51- 69 ,(2010) , 10.1111/J.1582-4934.2009.00991.X
Takayuki Kosaka, Yasushi Yatabe, Hideki Endoh, Kimihide Yoshida, Toyoaki Hida, Masahiro Tsuboi, Hirohito Tada, Hiroyuki Kuwano, Tetsuya Mitsudomi, Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib Clinical Cancer Research. ,vol. 12, pp. 5764- 5769 ,(2006) , 10.1158/1078-0432.CCR-06-0714
Hisayuki Shigematsu, Adi F. Gazdar, Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers International Journal of Cancer. ,vol. 118, pp. 257- 262 ,(2006) , 10.1002/IJC.21496
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi, Stefania Bartolini, Giovanni L. Ceresoli, Lynne Bemis, Jerry Haney, Samir Witta, Kathleen Danenberg, Irene Domenichini, Vienna Ludovini, Elisabetta Magrini, Vanesa Gregorc, Claudio Doglioni, Angelo Sidoni, Maurizio Tonato, Wilbur A. Franklin, Lucio Crino, Paul A. Bunn, Marileila Varella-Garcia, Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 97, pp. 643- 655 ,(2005) , 10.1093/JNCI/DJI112
C Mascaux, N Iannino, B Martin, M Paesmans, T Berghmans, M Dusart, A Haller, P Lothaire, A-P Meert, S Noel, J-J Lafitte, J-P Sculier, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis British Journal of Cancer. ,vol. 92, pp. 131- 139 ,(2005) , 10.1038/SJ.BJC.6602258
Gregory J. Riely, Mark G. Kris, Daniel Rosenbaum, Jenifer Marks, Allan Li, Dhananjay A. Chitale, Khedoudja Nafa, Elyn R. Riedel, Meier Hsu, William Pao, Vincent A. Miller, Marc Ladanyi, Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical Cancer Research. ,vol. 14, pp. 5731- 5734 ,(2008) , 10.1158/1078-0432.CCR-08-0646
Chen Mao, Li-Xin Qiu, Ru-Yan Liao, Fang-Bing Du, Hong Ding, Wan-Chun Yang, Jin Li, Qing Chen, None, KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies Lung Cancer. ,vol. 69, pp. 272- 278 ,(2010) , 10.1016/J.LUNGCAN.2009.11.020
Janiel M. Shields, Kevin Pruitt, Aidan McFall, Amy Shaub, Channing J. Der, Understanding Ras: ‘it ain’t over ’til it’s over’ Trends in Cell Biology. ,vol. 10, pp. 147- 154 ,(2000) , 10.1016/S0962-8924(00)01740-2